14 Biotech Stocks with High Potential

Page 11 of 13

3. Immunovant, Inc. (NASDAQ:IMVT)

Analyst Upside: 163.31%

Number of Hedge Fund Holders: 31

Immunovant, Inc. (NASDAQ:IMVT) is one of the best biotech stocks with high potential. On September 30, JPMorgan analyst Brian Cheng lowered the firm’s price target on Immunovant, Inc. (NASDAQ:IMVT) to $33 from $37 while keeping an Overweight rating on the shares.

Immunovant, Inc. (NASDAQ:IMVT) reported that its cash and cash equivalents totaled approximately $598.9 million in the quarter ending June 30, 2025, providing runway for announced indications through GD readout expected in 2027.

Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn).

Page 11 of 13